Identification of Nvp-Bkm120 As a Potent, Selective, Orally Bioavailable Class I P13 Kinase Inhibitor for Treating Cancer
Journal Article
·
· J. Biol. Inorg. Chem. 16:857,2011
OSTI ID:1089698
- Research Organization:
- SLAC National Accelerator Lab., Menlo Park, CA (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC)
- DOE Contract Number:
- AC02-76SF00515
- OSTI ID:
- 1089698
- Report Number(s):
- SLAC-REPRINT-2013-391
- Journal Information:
- J. Biol. Inorg. Chem. 16:857,2011, Journal Name: J. Biol. Inorg. Chem. 16:857,2011
- Country of Publication:
- United States
- Language:
- English
Similar Records
Identification of Nvp-Bkm120 As a Potent, Selective, Orally Bioavailable Class I P13 Kinase Inhibitor for Treating Cancer
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Journal Article
·
Fri Aug 09 00:00:00 EDT 2013
· ACS Med. Chem. Lett. 2:774,2011
·
OSTI ID:1089698
+18 more
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Journal Article
·
Wed Sep 18 00:00:00 EDT 2013
· J. Med. Chem.
·
OSTI ID:1089698
+17 more
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Journal Article
·
Tue Jul 10 00:00:00 EDT 2012
· Journal of Medicinal Chemistry
·
OSTI ID:1089698
+17 more